The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
QALSODY Biogen Australia Pty Ltd
Product name
QALSODY
Sponsor
Accepted date
Jan-2025
Active ingredients
tofersen
Proposed indication
QALSODY is used to treat amyotrophic lateral sclerosis that is linked to a mutation in the SOD1 gene.
Application type
A (new medicine)
Publication date
Jan-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.